Key Highlights

  • Peter Griffith, Amgen’s finance chief since 2020, will retire in September 2026 after six years at the helm
  • Thomas Dittrich, previously Galderma’s CFO, will succeed Griffith under a package reportedly worth $12.4m
  • Amgen (Nasdaq:AMGN) shares slipped 0.4% in pre-market trading on the succession news
  • The move underscores the widening talent competition between legacy biotechs and dermatology specialists
  • Analysts question whether the steep pay premium will translate into faster strategic execution

A Leadership vacuum and a costly lure

Amgen (NASDAQ:AMGN) on Tuesday disclosed that Peter Griffith, its executive vice-president and chief financial officer since 2020, will retire effective September 1st 2026. In a classic reverse handover, the Thousand Oaks-based giant has tapped Thomas Dittrich—most recently CFO of Galderma, a Swiss dermatology specialist owned by Nestlé and private-Equity firm Permira—reportedly luring him with a hefty $12.4m package. The figure, disclosed in regulatory filings and confirmed by people familiar with the matter, includes a mix of cash, restricted stock units, and performance-based equity vesting over three years. While Amgen has not published the full breakdown, industry norms for such “golden hellos” in biotech typically range between $5m-$10m for CFO-level recruits; the $12.4m signals both urgency and ambition.

The succession timeline is unusually stretched—Griffith will stay on until Dittrich formally assumes the CFO title on September 1st 2026, a six-month overlap intended to smooth the transition. Analysts at Jefferies noted in a client note that such long runways are rare among top-20 biopharmas, suggesting that Amgen’s board is prioritising stability over speed. Yet the extended transition also underscores the depth of the challenge: Griffith, a former Goldman Sachs banker, leaves behind a finance team that has overseen $70bn in acquisitions since 2020, including the $28bn buy-out of Horizon Therapeutics.

Why Galderma—and why now?

Dittrich’s move from Galderma to Amgen is the latest in a quiet but accelerating exodus of finance talent from dermatology specialists—where margins are rich and deal-making is frequent—to larger, diversified biotechs. Galderma, itself the product of a 2019 Carve-Out from Nestlé and now majority-owned by Permira, has been a Training ground for executives who parlay dermatology P&L experience into broader biotech roles. The Swiss outfit posted 2025 net Revenue of $5.7bn, up 10% year-on-year, driven by blockbuster drugs such as Epiduo and Restylane. Yet, despite its growth, Galderma’s ownership structure and governance have limited Dittrich’s upward mobility, insiders say.

Amgen, by contrast, is hunting for a CFO capable of steering a $77bn market-cap juggernaut through a period of Patent cliffs, pipeline pressures, and intensifying competition from generics and Biosimilars. The company’s Humira biosimilar launch in 2023 was pivotal—generating $3.7bn in 2025 revenue—but future growth hinges on late-stage Assets like sotorasib for KRAS-mutated cancers and the experimental AMG 570 for lupus. “The CFO role at Amgen is less about dermatology and more about Capital allocation across a $40bn R&D budget,” said Leerink Partners analyst Geoffrey Porges. Dittrich’s experience in high-Margin dermatology may yet prove an asset in negotiating licensing deals with smaller biotechs—a core part of Amgen’s open-innovation strategy.

Investor jitters and governance optics

The news sent Amgen (NASDAQ:AMGN) shares down 0.4% in pre-market trading on Tuesday, a modest underperformance relative to the broader biotech index, which slipped 0.2%. Investors are parsing whether the hefty compensation package signals confidence in Dittrich’s ability to accelerate Amgen’s strategic pivot—or whether it reflects desperation in the face of leadership turnover. Griffith’s departure marks the second high-profile exit this year, following the surprise resignation of Amgen’s chief medical officer in January. The board has moved quickly to Fill the CFO role, a sign that governance risk is not being ignored.

Yet the optics are troubling for some governance watchers. The $12.4m figure, while not unprecedented in biotech (Regeneron paid $14m to recruit a CFO from Gilead in 2021), is roughly double the median CFO pay package for S&P 500 companies, according to ISS data. Amgen’s board has defended the move as “competitive and aligned with long-term value creation,” but proxy advisory firms are likely to scrutinise the equity vesting schedule for performance hurdles. “The risk is that the board is overpaying for a known quantity rather than taking a chance on an internal candidate,” said Glass Lewis analyst Mariam Zaidi.

The broader war for biotech finance talent

Dittrich’s hire is the latest in a string of CFO-level poaches that have reshaped the biotech talent map. In March, Vertex Pharmaceuticals (NASDAQ:VRTX) lured CFO Charlie Wagner from Gilead Sciences (NASDAQ:GILD) with a $10m package; in April, Biogen (NASDAQ:BIIB) recruited a former J&J executive with a $9.5m total compensation package. The trend reflects a tightening labour market for executives with both Big Pharma rigor and biotech agility—attributes that are increasingly rare as large diversified groups outbid pure-play drugmakers on compensation.

The competition is intensifying as legacy biotechs like Amgen face mounting pressure to replenish pipelines and defend margins. According to Evaluate Pharma, the top 20 biopharmas will lose $45bn in annual revenue to biosimilar erosion by 2028; filling the CFO role with an outsider steeped in dermatology—where pricing power is strong and competition is niche—may signal a deliberate shift in Amgen’s strategic focus. Yet the timing is delicate: Dittrich will arrive just as Amgen’s $30bn cash pile faces calls from activists to return capital to shareholders rather than deploy it in bolt-on acquisitions.

What comes next: integration and execution risk

The six-month transition window offers Dittrich a rare opportunity to embed himself in Amgen’s finance operations before assuming full control. His immediate priorities will include finalising the 2027 budget, navigating the company’s $5bn share-repurchase programme, and overseeing the integration of Horizon Therapeutics—a deal that closed in 2024 but whose synergies have yet to fully materialise. Analysts at Bernstein estimate that Amgen’s free Cash Flow could dip to $8bn in 2026 from $9.2bn in 2025, partly due to Horizon integration costs.

Yet the bigger test will be Dittrich’s ability to translate Amgen’s financial discipline into strategic boldness. The company’s pipeline is heavy with next-generation modalities—including bispecific antibodies and gene therapies—where capital efficiency and Risk tolerance are paramount. “The CFO’s role is no longer just about balance-sheet stewardship; it’s about shaping the company’s risk appetite and capital deployment,” said SVB Securities analyst David Risinger. If Dittrich can strike that balance, the $12.4m price tag may yet prove a bargain.